TargetMol

Debrisoquin sulfate

Product Code:
 
TAR-T31272
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T31272-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31272-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Debrisoquine is an antihypertensive drug similar to guanethidine.
CAS:
581-88-4
Formula:
C20H28N6O4S
Molecular Weight:
448.54
Purity:
0.98
SMILES:
OS(O)(=O)=O.NC(=N)N1CCc2ccccc2C1.NC(=N)N1CCc2ccccc2C1

References

1. Laine K, Tybring G, H?rtter S, Andersson K, Svensson JO, Wid?n J, Bertilsson L. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35. PubMed PMID: 11673748. 2. Hamelin BA, Turgeon J, Vall?e F, B?langer PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996 Nov;60(5):512-21. PubMed PMID: 8941024. 3. Lautenschlager MT, Viktor S, M?ller UA, Hoffmann A. [Comparison of serum concentrations of caffeine, 4-methylaminoantipyrine, sulfamethazine and debrisoquin following oral administration of these substances as a cocktail in type II diabetics before and after insulin therapy]. Pharmazie. 1996 Oct;51(10):750-3. German. PubMed PMID: 8999440. 4. Marandi T, Dahl ML, Kiivet RA, R?go L, Sj?qvist F. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacol Toxicol. 1996 May;78(5):303-7. PubMed PMID: 8737964.